GLP-3(rt)

How GLP-3(rt) is described to act.

GLP-3(rt) (LY3437943) is a single synthetic peptide reported to act as an agonist at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. Review articles frame the added glucagon receptor component as a route to increased energy expenditure and altered hepatic lipid handling alongside the incretin-mediated effects on insulin secretion and appetite signaling. In rodent tumour models, systemic and tumour-microenvironment immune reprogramming was reported alongside weight reduction, including elevated circulating IL-6, increased antigen-presenting cells and reduced immunosuppressive cell populations. The triple-agonist design is described in the literature as an attempt to combine complementary metabolic pathways within a single molecule.

Mechanistic descriptions summarize published in vitro and animal work. They are not a representation of efficacy or safety in any subject, and no administration guidance is given or implied.

A phase 2, double-blind, randomised, placebo-controlled trial in 338 adults with obesity, or with overweight plus a weight-related condition, measured percentage change in body weight from baseline at 24 weeks, with change at 48 weeks and categorical weight-reduction thresholds as secondary endpoints. A randomised phase 2a substudy in 98 participants with metabolic dysfunction-associated steatotic liver disease measured mean relative change in liver fat at 24 weeks and reported reductions ordered by dose group versus placebo that tracked with changes in body weight, abdominal fat and measures of insulin sensitivity. A systematic review and meta-analysis pooled four randomised controlled trials and described a dose-dependent relationship across the outcomes analysed, with a safety profile the authors judged comparable to control. Narrative reviews have flagged dose-dependent increases in heart rate and reports of mild to moderate cardiac arrhythmia as reasons that long-term cardiovascular outcome trials are considered necessary. In preclinical pancreatic and lung tumour models, treated mice showed reduced tumour engraftment, delayed tumour onset and attenuated progression relative to controls, with the anti-tumour effect persisting after withdrawal. A 40-week phase 3, randomised, double-blind, placebo-controlled trial at 48 sites in the USA, Mexico and India (TRANSCEND-T2D-1) examined the compound as monotherapy in adults with type 2 diabetes inadequately controlled by diet and exercise alone, with baseline glycated haemoglobin between 7.0% and 9.5%. A post hoc exploratory analysis of two phase 2 datasets, comprising 282 and 213 participants, characterised fasting plasma metabolome and lipidome changes. A phase 2b mechanistic study in adults with overweight or obesity and chronic kidney disease (TRANSCEND-CKD) has published rationale, design and baseline characteristics ahead of results. A systematic review and meta-analysis of randomised controlled trials pooled blood pressure and lipid outcomes. A commentary in the internal medicine literature examines a reported urinary tract infection signal and whether its timing accounts for it. In isolated human right atrial preparations obtained during open heart surgery, force of contraction was measured, connecting the receptor pharmacology characterised in cell culture to a contractile endpoint in human tissue.

Cited literature is provided for scientific reference only and does not constitute a representation of efficacy or safety in any subject. All research findings presented are sourced from peer-reviewed journals and are provided for educational reference only.